☆ 4.7 Review

The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?

FRONTIERS IN ENDOCRINOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Radiology, Nuclear Medicine & Medical Imaging

Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms

Francesca Borgna et al.

Summary: The study found that [Tb-161]Tb-DOTA-LM3 was more effective in inhibiting tumor cell viability compared to [Lu-177]Lu-DOTA-LM3 in both in vitro and in vivo experiments. In mice studies, [Tb-161]Tb-DOTA-LM3 significantly delayed tumor growth and prolonged survival compared to [Lu-177]Lu-DOTA-LM3. Terbium-161 also showed therapeutic advantages over lutetium-177 when combined with DOTATOC.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

添加到收藏夹

Review Oncology

Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis

Jonathan Strosberg et al.

Summary: Re-treatment with Lu-177-PRRT showed encouraging median PFS in patients with NETs, with a safety profile similar to initial PRRT.

CANCER TREATMENT REVIEWS (2021)

添加到收藏夹

Article Oncology

177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

Jonathan R. Strosberg et al.

Summary: The NETTER-1 trial did not show a significant improvement in median overall survival with Lu-177-Dotatate treatment compared to high-dose long-acting octreotide, however, there was an 11.7 month difference which could be considered clinically relevant. No new safety signals were reported during long-term follow-up.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors

Silvia Nicolini et al.

Summary: The combination of Lu-177-DOTATATE with metronomic capecitabine shows promising efficacy and tolerability in patients with aggressive FDG-positive G1-G3 GEP-NETs, laying the groundwork for future randomized studies.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy

Richard P. Baum et al.

Summary: The Lu-177-DOTA-LM3 treatment in patients with metastatic neuroendocrine neoplasms showed promising results with good safety profile and efficacy outcomes, providing a potential alternative for PRRT with favorable biodistribution and higher tumor radiation doses than SSTR agonists.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome

Wouter T. Zandee et al.

Summary: PRRT treatment effectively reduced diarrhea and flushing in patients with carcinoid syndrome, making it a possible option for symptomatic treatment in cases where somatostatin analogs are not fully controlling symptoms.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE

Jonathan R. Strosberg et al.

Summary: Treatment with Lu-177-DOTATATE resulted in a significant reduction in abdominal pain, diarrhea, and flushing symptoms compared to high-dose octreotide LAR, supporting its beneficial impact on health-related quality of life in patients with progressive midgut neuroendocrine tumors.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparison of Nausea and Vomiting Associated With Amino Acid Formulations Coinfused With Peptide Receptor Radionuclide Therapy Commercial Parenteral Nutrition Formulas Versus Compounded Arginine/Lysine

Taymeyah Al-Toubah et al.

Summary: Co-infusion of arginine/lysine with radiolabeled somatostatin analogs significantly reduces rates of nausea/vomiting in patients compared to commercial amino acid formulations designed for parenteral nutrition. Additionally, infusion durations are substantially shorter, and infusion-related reactions are less frequent with arginine/lysine co-infusion.

PANCREAS (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches

Andrea Lania et al.

Summary: Neuroendocrine neoplasms (NENs) are a diverse group of tumors that require a multidisciplinary approach for treatment, with surgery being the only curative option. In recent years, neoadjuvant chemo(radio)therapy has become a standard in cancer treatment, but its efficacy and safety in NEN patients remain uncertain.

FRONTIERS IN ENDOCRINOLOGY (2021)

添加到收藏夹

Article Oncology

Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study

Golmehr Sistani et al.

Summary: Peptide receptor radionuclide therapy (PRRT) is an established treatment option for progressive neuroendocrine tumors (NETs). This phase 2 trial aimed to expand the use of PRRT to different types of NETs and evaluate the value of maintenance therapy. Results showed that adding low dose maintenance therapy significantly improved median progression-free survival compared to the NETTER-1 trial.

CURRENT ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors

Satya Das et al.

Summary: Research on GEP NET in recent years has shown that the development of new drugs such as PRRT and RTKIs holds great promise and may improve treatment outcomes for patients. Immunotherapy is also seen as a treatment direction, and some new approaches may be realized for clinical use in the future, further improving the survival prospects of patients.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Peptide Receptor Radionuclide Therapy With Lu-177-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome

Wouter T. Zandee et al.

Summary: PRRT with Lu-177-DOTATATE effectively reduced diarrhea and flushing in patients with carcinoid syndrome, showing potential as a symptomatic treatment option for patients whose symptoms are not well controlled with somatostatin analogs.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms

Johannes Hofland et al.

ENDOCRINE REVIEWS (2020)

添加到收藏夹

Article Oncology

Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up y

M. Pavel et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients

Jingjing Zhang et al.

JOURNAL OF NUCLEAR MEDICINE (2019)

添加到收藏夹

Article Oncology

Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study

Esben Andreas Carlsen et al.

ENDOCRINE-RELATED CANCER (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances

Amr Mohamed et al.

JOURNAL OF NUCLEAR MEDICINE (2019)

添加到收藏夹

Article Oncology

Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan

Diane Reidy-Lagunes et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013-2015

Tracey S. E. Genus et al.

BRITISH JOURNAL OF CANCER (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States

Mi Ri Lee et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

New Developments in Peptide Receptor Radionuclide Therapy

Guillaume P. Nicolas et al.

JOURNAL OF NUCLEAR MEDICINE (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis

Sue Ping Thang et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study

Guillaume P. Nicolas et al.

JOURNAL OF NUCLEAR MEDICINE (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Investigation of receptor radionuclide therapy with Lu-177-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index

Silvia Nicolini et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)

添加到收藏夹

Article Oncology

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial

Jonathan Strosberg et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article

Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor

Nupur K. Purohit et al.

Oncotarget (2018)

添加到收藏夹

Article Pathology

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

Guido Rindi et al.

MODERN PATHOLOGY (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

The safety of available treatments options for neuroendocrine tumors

A. Faggiano et al.

EXPERT OPINION ON DRUG SAFETY (2017)

添加到收藏夹

Article Medicine, General & Internal

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

J. Strosberg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

Arvind Dasari et al.

JAMA ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

James C. Yao et al.

LANCET (2016)

添加到收藏夹

Article Medicine, Research & Experimental

[Lu-177-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide (Lu-177-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study

Richard P. Baum et al.

THERANOSTICS (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

Lisa Bodei et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)

添加到收藏夹

Article Medicine, General & Internal

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

Martyn E. Caplin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Review Gastroenterology & Hepatology

Animal Models and Cell Lines of Pancreatic Neuroendocrine Tumors

Varsha Babu et al.

PANCREAS (2013)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors

Thorsten D. Poeppel et al.

JOURNAL OF NUCLEAR MEDICINE (2011)

添加到收藏夹

Article Medicine, General & Internal

Everolimus for Advanced Pancreatic Neuroendocrine Tumors.

James C. Yao et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.